AU2005323435A1 - Anti-coronavirus compounds - Google Patents

Anti-coronavirus compounds Download PDF

Info

Publication number
AU2005323435A1
AU2005323435A1 AU2005323435A AU2005323435A AU2005323435A1 AU 2005323435 A1 AU2005323435 A1 AU 2005323435A1 AU 2005323435 A AU2005323435 A AU 2005323435A AU 2005323435 A AU2005323435 A AU 2005323435A AU 2005323435 A1 AU2005323435 A1 AU 2005323435A1
Authority
AU
Australia
Prior art keywords
compound
aryl
heterocycloalkyl
independently
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2005323435A
Other languages
English (en)
Inventor
Jia-Tsrong Jan
Chi-Huey Wong
Chung-Yi Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Academia Sinica
Original Assignee
Academia Sinica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Academia Sinica filed Critical Academia Sinica
Publication of AU2005323435A1 publication Critical patent/AU2005323435A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2005323435A 2004-05-04 2005-05-03 Anti-coronavirus compounds Abandoned AU2005323435A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56808004P 2004-05-04 2004-05-04
US60/568,080 2004-05-04
PCT/US2005/015227 WO2006073456A2 (en) 2004-05-04 2005-05-03 Anti-coronavirus compounds

Publications (1)

Publication Number Publication Date
AU2005323435A1 true AU2005323435A1 (en) 2006-07-13

Family

ID=36647910

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005323435A Abandoned AU2005323435A1 (en) 2004-05-04 2005-05-03 Anti-coronavirus compounds

Country Status (7)

Country Link
US (1) US8481571B2 (enExample)
JP (1) JP2007536240A (enExample)
CN (1) CN1949977B (enExample)
AU (1) AU2005323435A1 (enExample)
NZ (1) NZ550945A (enExample)
TW (1) TWI372048B (enExample)
WO (1) WO2006073456A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2856708C (en) * 2011-11-25 2022-01-11 Bayer Intellectual Property Gmbh Antibacterial tylosin derivatives and methods for their preparation
CA2875975A1 (en) * 2012-06-06 2013-12-12 Unither Virology, Llc Novel iminosugars and their applications
WO2017059118A1 (en) * 2015-09-29 2017-04-06 Duke University Compositions and methods for identifying and treating dystonia disorders
US20190282558A1 (en) * 2016-05-16 2019-09-19 Emergent Virology Llc Methods of Treating Zika Virus Infection
CN107595906B (zh) * 2017-11-10 2020-10-30 中国药科大学 常春藤皂苷元及其糖苷在制备抗病毒的药物中的应用
AU2020289560A1 (en) 2019-06-05 2021-12-23 Emory University Peptidomimetics for the treatment of coronavirus and picornavirus infections
IL297069A (en) * 2020-04-10 2022-12-01 Cocrystal Pharma Inc Replication inhibitors of norovirus and corona virus
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors
CN117402204A (zh) * 2022-07-07 2024-01-16 北京大学 三萜类化合物及其抗病毒用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5142056A (en) * 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
JPH0778021B2 (ja) * 1988-04-13 1995-08-23 太陽化学株式会社 下痢症ウイルス感染阻害剤
US5156973A (en) * 1988-11-23 1992-10-20 Edward Shanbrom Antiviral blood sampling process and apparatus
JPH07502970A (ja) 1990-06-01 1995-03-30 ザ・デュポン・メルク・ファーマシュウティカル・カンパニー １，４―ジアミノ―２，３―ジヒドロキシブタン類
JPH04297475A (ja) * 1991-03-26 1992-10-21 Yamanouchi Pharmaceut Co Ltd 抗ウイルス剤
US6803466B1 (en) 1997-12-08 2004-10-12 The Scripps Research Institute HIV/FIV protease inhibitors having a small P3 residue

Also Published As

Publication number Publication date
CN1949977A (zh) 2007-04-18
US20060160866A1 (en) 2006-07-20
CN1949977B (zh) 2010-09-29
WO2006073456A3 (en) 2006-09-14
TW200600084A (en) 2006-01-01
US8481571B2 (en) 2013-07-09
TWI372048B (en) 2012-09-11
JP2007536240A (ja) 2007-12-13
NZ550945A (en) 2010-04-30
WO2006073456A2 (en) 2006-07-13

Similar Documents

Publication Publication Date Title
US11970502B2 (en) Macrocyclic antiviral agents
ES2347822T3 (es) Inhibidores de replicacion de vhc.
TWI438200B (zh) Ｃ型肝炎病毒抑制劑
KR101614964B1 (ko) Ｃ형 간염 바이러스 억제제로서 사용하기 위한 형태적으로 제한된 바이페닐 유도체
CN103827108B (zh) 丙型肝炎病毒抑制剂
RO119413B1 (ro) Derivaţi izosteri ai substratului aspartat proteazei, sărurile lor, compoziţii farmaceutice şi utilizare
US9464064B2 (en) HCV helicase inhibitors and methods of use thereof
CN102459239A (zh) 丙型肝炎病毒抑制剂
US8481571B2 (en) Anti-coronavirus compounds
CN117836272A (zh) 用于治疗或预防冠状病毒感染的3cl蛋白酶小分子抑制剂及其用途
CN115160301B (zh) 一种山荷叶素衍生物、其制备方法及用途
HRP20000532A2 (en) Novel naphthyl-substituted and anilide-substituted sulfonamides
EP4052726B1 (en) Cd4 mimic compound with anti-hiv activity
WO2022022448A1 (zh) 神经氨酸酶抑制剂类化合物、其药物组合物及其用途
CN1336934A (zh) 用作hiv蛋白酶抑制剂的含有n－末端取代苄基的双氨基酸磺胺
AU722489B2 (en) (4r,5s,6s,7r)-hexahydro-1- {5-(3-aminoinazole)methyl} -3-butyl-5,6-dihydr oxy-4,7-bis {phaenylmethyl} -2h-1,3-diazepin-2-one, its preparation and its use as HIV protease inhibitor
US6218386B1 (en) A1-(3-aminoindazol-5-yl)-3 butyl-cyclic urea useful as a HIV protease inhibitor
US12582619B2 (en) Compounds, compositions, and methods for treating or ameliorating, or preventing viral infections
KR20000053122A (ko) Ｈｉｖ 프로테아제 억제제로 유용한 1-(3-아미노인다졸-5-일)-3-페닐메틸-시클릭 우레아
WO2024252327A1 (en) Solid forms of n-(methoxycarbonyl)-3-methyl-l-valyl-(4 r)- n-{(1 s)-1-cyano-2-[(3 s)-2-oxopyrrolidin-3-yl]ethyl}-4-(trifluoromethyl)-l-prolinamide and solvates thereof
WO2023232048A1 (zh) 喜树碱前药及其药物组合物
WO2015143535A1 (en) Small molecule inhibitors of gp120-mediated hiv infection and methods of use
LT4676B (lt) 1-(3-aminoindazol-5-il)-3-fenilmetil-cikliniai karbamidai, naudojami kaip živ proteazės inhibitoriai
LT4619B (lt) (4r,5s,6s,7r)-heksahidro-1-[5-(3-aminoinazol)metil]-3-butil-5, 6-dihidroksi-4,7-bis[fenilmetil]-2h-1,3-diazepin-2-onas, jo gavimas ir jo kaip živ proteazės inhibitoriaus panaudojimas

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application